METHODS FOR TREATING NON-ALCOHOLIC STEATHEPATITIS (NASH) USING THE MODIFIED FIBROBLAST 21 GROWTH FACTOR (FGF-21)

摘要

The present invention relates to methods for treating a patient with NASH who has been determined to have a specific threshold level of serum Pro-C3 (e.g., greater than 10 ng / ml) by administering to the patient a modified fibroblast growth factor 21 (FGF-21) in quantity and frequency sufficient to treat NASH. The present invention also relates to methods for monitoring the ability of a patient with NASH to respond to treatment with modified FGF-21, the method comprising determining a serum level of Pro-C3 in a patient's blood sample obtained during or after treatment, wherein a reduced serum level of Pro-C3 in a sample The patient’s blood obtained during or after treatment, compared with the serum level of Pro-C3 in the patient’s blood sample obtained before treatment with modified FGF-21, indicates that the patient is able to respond to treatment with modified FGF-21.